The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.
 
Jaydira Del Rivero
No Relationships to Disclose
 
Kimberly Perez
Consulting or Advisory Role - Celgene; Eisai; Helsinn Therapeutics/QED Therapeutics; Lantheus Medical Imaging
 
Susan Michelle Geyer
Research Funding - Brisol-Myers-Squibb (Inst); Celgene (Inst); Johnson & Johnson/Janssen (Inst)
 
Maged F. Khalil
No Relationships to Disclose
 
Aishwarya Vijendran
No Relationships to Disclose
 
Andrea Kordaris-Corkill
No Relationships to Disclose
 
Ardaman Shergill
Honoraria - ASCO; Cholangiocarcinoma Foundation; cholangiocarcinoma summit; Curio Science; oklahoma society of clinical oncology; OncLive/MJH Life Sciences; saint joseph hospital Chicago
Consulting or Advisory Role - Catalyst Pharmaceuticals; KLJ Associates; Pfizer; Triptych Health Partners
Research Funding - Astellas Pharma (Inst); BMS (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); Macrogenics (Inst); Merck (Inst); Oncologie (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); TP Therapeutics (Inst); verastem (Inst)
 
Kristen Renee Spencer
Honoraria - Lynx Group; Society for Immunotherapy of Cancer
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Helsinn Therapeutics; International Society of Gastrointestinal Oncology; Lynx Group
Research Funding - Winn CDA
Travel, Accommodations, Expenses - ASCO
 
Heloisa P. Soares
Consulting or Advisory Role - AstraZeneca; Exelixis; Helsinn Therapeutics; Incyte; Ipsen; Pfizer; TerSera
(OPTIONAL) Uncompensated Relationships - NCCN; North American Neuroendocrine Tumor Society
 
Charles D. Lopez
Research Funding - Roche/Genentech (Inst); Servier (Inst); Taiho Pharmaceutical (Inst)
 
Andrew B. Nixon
Consulting or Advisory Role - AdjuVolt; Leap Therapeutics; Promega
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Genmab (Inst); HTG Molecular Diagnostics (Inst); medpacto (Inst); Promega (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
 
Amylou C. Dueck
No Relationships to Disclose
 
Jeffrey A. Meyerhardt
Honoraria - Merck
Research Funding - Boston Biomedical (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - AstraZeneca; Autem Medical (I); Boehringer Ingelheim; Eisai (I); Exelixis (I); Genentech/Roche (I); Helio Health (I); Incyte (I); Ipsen; Merck; Novartis; QED Therapeutics (I); Yiviva (I); Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma